Clinical trials: Continuous Insulin Infusion System
Type 1 Diabetes Mellitus, Pregnancy
Orchestra Pregnancy Observational Study in Poland
The aim of this project is to document the use of insulin pump therapy (CSII), including sensor augmented pump therapy (SAP), before, during and after pregnancy in women with type 1 Diabetes Mellitus benefiting from the Orchestra…
- Trial name
- NCT01779141
- Where
- 24 sites in Poland
- Volunteers
- 481 people
- Sponsor
- Medtronic MiniMed, Inc.
Diabetes, Type I
12 Week,Comparing Safety of HMR1964 & Insulin Aspart Used in Continuous Subcutaneous Infusion in Type 1 Diabetes.
The purpose of this study is to compare the safety of HMR 1964 and insulin aspart when used in external pumps with respect to catheter occlusions, GHb assessment, insulin doses, blood glucose parameters, hypoglycemic episodes…
- Trial name
- NCT00046150
- Testing
- Insulin glulisine (HMR1964)
- Where
- 3 sites in France, Germany and 1 more
- Volunteers
- 59 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Pharmacokinetics/Dynamics of Basal (Continuous) Insulin Infusion Administered Either Intradermally or Subcutaneously
The primary objective of this study will be to assess the PK/PD responsiveness of basal ID administered insulin compared to SC, and to determine the safety and local tolerability of extended (two six-hour periods) microneedle…
- Trial name
- NCT01061216
- Testing
- Intradermal insulin delivery: BD Research Catheter Set, Subcutaneous insulin delivery:ACCU-CHEK Rapid-D Infusion Set
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- Becton, Dickinson and Company
Type 1 Diabetes Mellitus
VV-14299 and VV-14300 for the Treatment of Type 1 Diabetes
This study is testing VV-14299 and VV-14300 or VV-14300 alone in adults with long-standing type 1 diabetes (T1D) whose blood sugar is not well controlled despite using an automated insulin delivery (AID) system.
- Trial name
- PROGRESS (NCT07829302)
- Testing
- VV-14300, VV-14299
- Where
- Australia
- Volunteers
- 29 people
- Sponsor
- Kriya Therapeutics, Inc.
Diabetes Mellitus
A Study of DIA:CONN P8 Smart Insulin Pen With CGM-Based Coaching in Patients With Type 1 or Type 2 Diabetes
A Study of DIA:CONN P8 Smart Insulin Pen With CGM-Based Coaching in Patients With Type 1 or Type 2 Diabetes
- Trial name
- NCT07004153
- Testing
- Smart Coaching Insulin Pen
- Where
- South Korea
- Volunteers
- 152 people
- Sponsor
- G2e Co., Ltd
Diabetes Mellitus, Type 1
A Study to Test How Insulin NNC0471-0119 H Works in the Body in Participants With Type 1 Diabetes When Given by an Insulin Pump
The study is looking at the effect and safety of a new fast-acting insulin (NNC0471 0119) to people with type 1 diabetes when given by an insulin pump.
- Trial name
- NCT06809621
- Testing
- NNC0471-0119 H, Insulin aspart
- Where
- Germany
- Volunteers
- 43 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
A Study to Test How Insulin NNC0471-0119 H Works in the Body in Participants With Type 2 Diabetes When Given by an Insulin Pump
This study looks at the effect and safety of a new fast-acting insulin (NNC0471-0119) in people with type 2 diabetes when given by an insulin pump.
- Trial name
- NCT07068295
- Testing
- NNC0471-0119 H, Insulin Aspart
- Where
- Germany
- Volunteers
- 65 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 1
A Study of LY900014 Versus Insulin Lispro (Humalog) on High Blood Sugar in Participants With Type 1 Diabetes Who Use Insulin Pumps
The main purpose of this study is to compare LY900014 to insulin lispro (Humalog) in participants with type 1 diabetes who are using an insulin pump and have high blood sugar after eating.
- Trial name
- NCT04276207
- Testing
- LY900014, Insulin Lispro
- Where
- Germany
- Volunteers
- 32 people
- Sponsor
- Eli Lilly and Company
Type 1 Diabetes, Type 2 Diabetes
Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System
The purpose of this study is to demonstrate point accuracy of the Abbott Sensor Based Glucose Monitoring (GM) System interstitial glucose results against Reader capillary Blood Glucose (BG) reference using the Consensus Error…
- Trial name
- NCT02073058
- Testing
- No treatment
- Where
- 4 sites in United States
- Volunteers
- 75 people
- Sponsor
- Abbott Diabetes Care
Diabetes Mellitus, Type 1
YpsoPump Occlusion Detection Algorithm: Collection of Real-world Data for In-silico Evaluation of a New Software Algorithm to Refine Occlusion Detection in Subjects With Type 1 Diabetes Using Continuous Subcutaneous Insulin Infusion
A common difficulty related to the insulin pumps are occlusions of the insulin infusion set (IIS). This study aims to evaluate the performance of a new software algorithm to detect catheter-occlusion in silico in order to refine…
- Trial name
- NCT05096325
- Testing
- YpsoPump® insulin pump system
- Where
- 2 sites in Germany, Switzerland
- Volunteers
- 40 people
- Sponsor
- mylife Diabetes Care AG
Diabetes, Diabetes Mellitus, Type 1
A Research Study of How Faster-acting Insulin Aspart Moves Into, Through, and Out of the Body and How it Works in the Body When Given Through an Insulin Pump to People With Type 1 Diabetes
The aim of the study is to compare the pharmacokinetics (i.e. the course of the blood concentrations of the administered trial drug) of faster-acting insulin aspart (faster aspart), and the currently marketed formulation of…
- Trial name
- NCT03215498
- Testing
- Faster-acting insulin aspart, Insulin aspart
- Where
- Germany
- Volunteers
- 58 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 1
Effect of Insulin Glulisine Compared to Insulin Aspart and Insulin Lispro When Administered by Continuous Subcutaneous Insulin Infusion (CSII) on Specific Pump Parameters in Patient With Type 1 Diabetes Mellitus
Primary objective: To demonstrate the superiority of insulin glulisine over insulin aspart and insulin lispro administered by external pump in term of unexplained hyperglycemia and/or infusion set occlusion.
- Trial name
- PUMP (NCT00607087)
- Testing
- Insulin glulisine, Insulin lispro, Insulin aspart
- Where
- 12 sites in United States, Australia and 10 more
- Volunteers
- 289 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 1
A Study to Look at How Insulin NNC0471-0119 Works in the Body in People With Type 1 Diabetes When Injected by Insulin Pump
This study is looking at the effect and safety of 3 formulations of the new rapid-acting insulin analogue NNC0471-0119, for the treatment of type 1 diabetes when given by insulin pump.
- Trial name
- NCT05262595
- Testing
- NNC0471-0119 A, NNC0471-0119 B, NNC0471-0119 D
- Where
- Austria
- Volunteers
- 19 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus Type 1
Comparing Continuous Subcutaneous Insulin Infusion With Multiple Daily Injections to Reach HbA1c Targets in Children and Adolescents With Type 1 Diabetes
This study is to compare metabolic control, treatment satisfaction, and quality of life during continuous subcutaneous insulin infusion (CSII ) therapy with a new insulin pump system with multiple daily injections (MDI) therapy.
- Trial name
- Insight Kids (NCT02403375)
- Testing
- Accu-Chek Insight Pump System
- Where
- 9 sites in Austria, Germany and 1 more
- Volunteers
- 43 people
- Sponsor
- Hoffmann-La Roche
Diabetes Mellitus, Type 1, Type 1 Diabetes
"FEXIS": (Feasibility of an Extended Wear CSII Set in Participants With T1DM)
Over 1 million patients globally currently manage their Type 1 Diabetes mellitus using continuous subcutaneous insulin infusion with an infusion set that needs to be changed every 3 days.
- Conditions
- Diabetes Mellitus, Type 1, Type 1 Diabetes, Type 1 Diabetes Mellitus, Diabetes Mellitus, Insulin-Dependent, 1
- Trial name
- FEXIS (NCT04503564)
- Testing
- coil-reinforced soft polymer indwelling cannula
- Where
- Australia
- Volunteers
- 20 people
- Sponsor
- Capillary Biomedical, Inc.
Diabetes Mellitus, Type 1, Type 1 Diabetes
Pharmacokinetics (PK)/ Pharmacodynamics (PD) of an Extended Wear Infusion Set for Continuous Subcutaneous Insulin Infusion (CSII) in Type 1 Diabetes Mellitus (T1DM) Patients ("PEXIS")
This study has been designed as a prospectively enrolled, randomized sequence, 2-way crossover study of device performance, tolerability and safety of an investigational insulin infusion set using a coil-reinforced soft polymer…
- Trial name
- NCT04398030
- Testing
- coil-reinforced soft polymer indwelling cannula, soft Teflon indwelling catheter
- Where
- United States
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- Capillary Biomedical, Inc.
Diabetes Mellitus, Type 1
A Study of LY900014 (Lyumjev) Versus Insulin Lispro (Humalog) in Participants With Type 1 Diabetes
This study will be conducted in participants with type 1 diabetes mellitus on continuous subcutaneous insulin infusion (CSII) or pump therapy to evaluate the effect of LY900014 (Lyumjev) on blood sugar levels during exercise…
- Trial name
- NCT05262387
- Testing
- Lyumjev with 50% basal rate reduction, Humalog with 50% basal rate reduction, Humalog with 100% basal rate reduction
- Where
- Canada
- Volunteers
- 25 people
- Sponsor
- Eli Lilly and Company
Type 1 Diabetes
Obtain a Good Blood Glucose Control With the Paradigm Real Time System
In this study, subjects with insufficient metabolic control despite optimized basal-bolus injection regimens were randomily assigned to either the Mini- Med Paradigm REAL-Time insulin pump (PRT), an insulin pump that can receive…
- Trial name
- RTD (NCT00441129)
- Testing
- Minimed paradigm Real Time Sytem, Minimed Paradigm 512/712 Insulin pump
- Where
- 8 sites in France
- Volunteers
- 115 people, healthy volunteers welcome
- Sponsor
- Medtronic MiniMed, Inc.
Quality of Life, Burden, Dependency
Impact of the Use of a Closed-loop Insulin Therapy on the Burden of the Diabetes and the Quality of Life
The use by diabetes patients of real-time Continuous Glucose Monitoring (CGM) system is becoming widespread and has changed diabetic practice. Automated closed-loop (CL) insulin therapy has come of age.
- Trial name
- IMPLIQUE (NCT04939766)
- Testing
- Activation of a closed loop device in an insulin pump device with GCM
- Volunteers
- 250 people
- Sponsor
- VitalAire
Diabetes Mellitus, Type 1
Evaluation of Accu-Chek DiaPort, a Port System for Continuous Intraperitoneal Insulin Infusion, in Patients With Type I Diabetes
The Accu-Chek DiaPort system enables continuous intraperitoneal insulin infusion (CIPII): that is, infusion of insulin into the peritoneal cavity using an Accu-Chek insulin pump and an infusion set.
- Trial name
- NCT01483352
- Testing
- Accu-Chek DiaPort
- Where
- Germany
- Volunteers
- 12 people
- Sponsor
- Hoffmann-La Roche